Investors sold shares of Johnson & Johnson (NYSE:JNJ) on strength during trading on Monday. $83.42 million flowed into the stock on the tick-up and $179.79 million flowed out of the stock on the tick-down, for a money net flow of $96.37 million out of the stock. Of all stocks tracked, Johnson & Johnson had the 3rd highest net out-flow for the day. Johnson & Johnson traded up $0.20 for the day and closed at $139.76

JNJ has been the topic of several analyst reports. UBS AG reiterated a “buy” rating and set a $148.00 price target (up previously from $136.00) on shares of Johnson & Johnson in a report on Wednesday, July 19th. Credit Suisse Group initiated coverage on shares of Johnson & Johnson in a report on Thursday, July 20th. They issued an “outperform” rating and a $148.00 price objective on the stock. BTIG Research lowered shares of Johnson & Johnson from a “neutral” rating to a “sell” rating and set a $110.00 price objective on the stock. in a report on Friday, July 21st. Atlantic Securities lowered shares of Johnson & Johnson from a “neutral” rating to an “underweight” rating and set a $113.00 price objective on the stock. in a report on Friday, July 21st. Finally, Alembic Global Advisors lowered shares of Johnson & Johnson from a “neutral” rating to an “underweight” rating in a report on Friday, July 21st. Four analysts have rated the stock with a sell rating, eight have assigned a hold rating and eleven have assigned a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average price target of $143.70.

The firm has a market capitalization of $374,930.72, a PE ratio of 19.55, a P/E/G ratio of 2.84 and a beta of 0.82. The company has a quick ratio of 1.02, a current ratio of 1.32 and a debt-to-equity ratio of 0.36.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Tuesday, October 17th. The company reported $1.90 EPS for the quarter, topping the Zacks’ consensus estimate of $1.80 by $0.10. Johnson & Johnson had a return on equity of 27.38% and a net margin of 21.28%. The business had revenue of $19.65 billion during the quarter, compared to the consensus estimate of $19.29 billion. During the same period in the previous year, the company posted $1.68 earnings per share. The business’s revenue for the quarter was up 10.3% on a year-over-year basis. equities research analysts anticipate that Johnson & Johnson will post 7.28 EPS for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 12th. Stockholders of record on Tuesday, November 28th will be given a dividend of $0.84 per share. This represents a $3.36 dividend on an annualized basis and a dividend yield of 2.41%. The ex-dividend date is Monday, November 27th. Johnson & Johnson’s dividend payout ratio is presently 58.33%.

Several institutional investors have recently made changes to their positions in the company. Vanguard Group Inc. grew its position in shares of Johnson & Johnson by 1.5% during the second quarter. Vanguard Group Inc. now owns 200,450,985 shares of the company’s stock worth $26,517,661,000 after buying an additional 3,023,110 shares in the last quarter. BlackRock Inc. grew its position in shares of Johnson & Johnson by 2.6% during the second quarter. BlackRock Inc. now owns 174,073,764 shares of the company’s stock worth $23,028,219,000 after buying an additional 4,332,612 shares in the last quarter. State Street Corp grew its position in shares of Johnson & Johnson by 4.3% during the first quarter. State Street Corp now owns 160,223,321 shares of the company’s stock worth $19,955,806,000 after buying an additional 6,656,371 shares in the last quarter. Bank of New York Mellon Corp boosted its holdings in Johnson & Johnson by 0.4% in the third quarter. Bank of New York Mellon Corp now owns 36,594,054 shares of the company’s stock valued at $4,757,593,000 after purchasing an additional 130,437 shares in the last quarter. Finally, FMR LLC boosted its holdings in Johnson & Johnson by 5.9% in the second quarter. FMR LLC now owns 27,237,648 shares of the company’s stock valued at $3,603,268,000 after purchasing an additional 1,509,745 shares in the last quarter. 65.93% of the stock is owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: “Investors Sell Shares of Johnson & Johnson (JNJ) on Strength (JNJ)” was first reported by Watch List News and is the property of of Watch List News. If you are accessing this piece of content on another site, it was illegally stolen and reposted in violation of United States & international trademark & copyright legislation. The original version of this piece of content can be read at https://www.watchlistnews.com/investors-sell-shares-of-johnson-johnson-jnj-on-strength-jnj/1701211.html.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with Analyst Ratings Network's FREE daily email newsletter.